On Demand 2016 Advanced Practice Health Care Providers Course General Session and Concurrent Workshops

You can earn up to 6.25 CBRN contact hours or AMA PRA Category 1 Credit(s)™. $100 $80 Members / $151 $121 Non-Members

This package is a collection of the sessions from the 2016 Advanced Practice Health Care Providers Course general sessions and workshops. 

  • Advanced Practice Health Care Providers Course General Session
  • AP2 Prescription and Nonprescription Therapy: The Good, the Bad, the Ugly 
  • AP3 Chronic Urticaria, Angioedema and HAE 

Release Date: 12/01/2016
Expiration Date: 11/30/2019


The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 6.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Provider approved by the California Board of Registered Nursing, Provider Number 14486 for 6.25 contact hours.

Learning Objectives

  • Define ACOS; and describe signs, symptoms (including spirometry) and treatment of ACOS
  • Summarize published updates on immunotherapy for food allergy; and discuss protocols, side effects and efficacy for this novel type of therapy
  • Evaluate several key articles presented in the past year’s literature which have implications for improving practice
  • Discuss emerging issues in the delivery of allergy care with review of federal and state laws regarding the USP chapter 797
  • Discuss what each practice should do to be in compliance with the new regulations
  • Discuss the initiative of precision medicine as it attempts to utilize data-driven information, viewing health as an intersection of human biology, behavior, genetics, environment, data science and computation, and much more to produce new knowledge with the goal of developing more effective ways to prolong health and treat disease
  • Review the recent studies suggesting the importance of steroid use in children
  • Define measures for best practice in managing children with asthma, including the consideration of those also receiving nasal and topical steroids
  • Describe the types of patients who would benefit from patch testing
  • Interpret results of patch testing and provide patient education
  • Compare and contrast the evidence for effectiveness to the risk of treatment in common prescription and nonprescription allergy/asthma therapies
  • Provide patient education regarding the risks and benefits of each recommendation
  • Describe presenting signs, symptoms and pathophysiology of CU, angioedema and HAE
  • Identify essential and contributory diagnostic laboratory testing in the workup of these patients
  • Discuss pharmacologic and nonpharmacologic treatment plan for managing urticaria and angioedema


Additional information

Jodi A. Shroba, MSN, APRN, CPNP -- Speaker: Meda

Charlotte M. Jacobsen, MSN, RN -- Consultant/Advisor: CSL Behring, Shire

Cheryl K. Bernstein, BSN, RN, CCRC -- Supported/Contracted Research: Amgen, AstraZeneca, Boehringer Ingelheim, CSL Behring, Circassia, Dyax, GlaxoSmithKline, MedImmune, Meda, Merck, Mylan, Novartis, Pfizer, Regeneron, Shire, Stallergenes, Teva

Deidra H. Sanders, RN, MSN, APRN, FNP-BC -- Consultant/Advisor: Meda, AllergyZone; Speaker: Meda

David P. Skoner, MD, FACAAI -- Consultant/Advisor: Greer, Meda, Merck, Mylan, Novartis; Speaker: Boehringer Ingelheim, Genentech, Greer, Meda, Merck, Mylan, Novartis, Sunovion; Supported/Contracted Research: AstraZeneca, GlaxoSmithKline, Greer, Merck, Sunovion

B. Gwen Carlton, DNP, FNP-BC, AE-C -- Speaker: Genentech

Maureen George, PhD, RN, AE-C, FAAN -- Consultant/Advisor: Teva; Speaker: Teva

Christine W. Wagner, RN, MSN, CPNP, AE-C -- Consultant/Advisor: Meda, Teva; Speaker: Meda, Teva

David I. Bernstein, MD, FACAAI -- Consultant/Advisor: Circassia, Merck, Novartis, Teva; Speaker: AstraZeneca, Merck; Supported/Contracted Research: Amgen, AstraZeneca, Forest, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Merck, Mylan, Novartis, Pfizer, Regeneron, Shire, Stallergenes, Teva

Mary Lou Hayden, RN, MS, FNP-BC, AE-C -- Consultant/Advisor: Boehringer Ingelheim, Meda, Teva; Speaker: Boehringer Ingelheim, Meda, Teva

The following have no financial relationship to disclose:

Kari C. Nadeau, MD, PhD

Robert F. Lemanske, MD, FACAAI

Kimberly G. Clay, RN, MSN, APRN, FNP-BC

Course summary
Available credit: 
  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN
Course opens: 
Course expires: 

Available Credit

  • 6.25 AMA PRA Category 1 Credit™
  • 6.25 Attendance
  • 6.25 CBRN


Please login or create an account to take this course.